Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer

BACKGROUND: Patients with lung cancer face a heightened risk of atherosclerosis-related cardiovascular events. Despite the strong scientific rationale, there is currently a lack of clinical evidence examining the impact of immune checkpoint inhibitors (ICIs) on the advancement of atherosclerosis in...

Descripción completa

Detalles Bibliográficos
Autores principales: Drobni, Zsofia Dora, Gongora, Carlos, Taron, Jana, Suero-Abreu, Giselle A, Karady, Julia, Gilman, Hannah K, Supraja, Sama, Nikolaidou, Sofia, Leeper, Nicolas, Merkely, Béla, Maurovich-Horvat, Pal, Foldyna, Borek, Neilan, Tomas G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347471/
https://www.ncbi.nlm.nih.gov/pubmed/37433718
http://dx.doi.org/10.1136/jitc-2023-007307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347471/
https://www.ncbi.nlm.nih.gov/pubmed/37433718
http://dx.doi.org/10.1136/jitc-2023-007307

Ejemplares similares